Dr. Aggarwal on study of androgen annihilation in biochemically relapsed prostate cancer


Rahul Aggarwal, MD, discusses the phase 3 PRESTO trial, which he presented at the 2022 ESMO Congress.

The study found that intensification of androgen-deprivation therapy (ADT) with the addition of the androgen receptor inhibitor apalutamide (Erleada) improved outcomes versus ADT alone in patients with high-risk biochemically relapsed prostate cancer.

The findings also showed, however, that while a third study arm of apalutamide/ADT plus acetate (Zytiga) and prednisone improved outcomes versus ADT alone, there was not a significant additional benefit with this regimen compared with the other experimental arm of just apalutamide/ADT.

Aggarwal is associate professor of Hematology/Oncology, University of California, San Francisco (UCSF), and associate director for Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center.

Related Videos
Dr. Sunil H. Patel in an interview with Urology Times
medical depiction of a human bladder
Dr. Sunil H. Patel in an interview with Urology Times
© 2023 MJH Life Sciences

All rights reserved.